Open AccessChronic Myeloid Leukemia in India
Author(s) -
Prasanth Ganesan,
Lalit Kumar
Publication year - 2017
Publication title -
journal of global oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.002
H-Index - 17
ISSN - 2378-9506
DOI - 10.1200/jgo.2015.002667
Subject(s) - medicine , imatinib , myeloid leukemia , context (archaeology) , population , imatinib mesylate , incidence (geometry) , epidemiology , disease , intensive care medicine , environmental health , paleontology , physics , optics , biology
In the last decade, the use of imatinib has brought a paradigm shift in the management of chronic myeloid leukemia (CML). In India, imatinib has been available for more than a decade and has been made accessible to all segments of the population because of patient assistance programs and cheaper generic versions. Despite improvements in survival, there are unique challenges in the Indian context.